We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Company Develops Series of Molecular Diagnostic Services

By Biotechdaily staff writers
Posted on 28 Jan 2008
A company has created a range of molecular diagnostic services for disease identification, disease predisposition, and personalized medicine through in-house development and an active program of in-licensing.

The UK-based company was originally set up to spearhead increased availability of state-of-the-art diagnostic tests for healthcare and environmental monitoring. More...
It is focusing its products and services in two key areas: healthcare diagnostics including personalized medicine and environmental diagnostics.

The molecular disease services offered by the company, which is called Lab21 (Cambridge and Newmarket, UK), comprise: liver disease, including hepatitis C and non-alcoholic syndromes; sexually transmitted diseases including syphilis; infectious diseases, such as HIV and malaria; cancer diagnostics including breast, skin, ovarian, and colorectal; and coronary heart disease and thrombosis.

In addition to these clinical tests and services, Lab21 is working in partnership with pharmaceutical and biotech companies, and contract research organizations (CROs) to provide molecular diagnostic support, pre-clinical and clinical research including pharmacogenetics. During 2008 Lab21 expects to secure new licensing agreements and launch new diagnostics tests, in particular in the ‘companion' diagnostics area. Companion diagnostics are growing in importance--they are tests that are used to determine the best therapeutic regime for a patient, allowing for a more personalized approach.

"Genomics and proteomics are enabling the development of medicines that are tailored either to the patients' unique profiles or that of the disease. Companion diagnostics are vital for such personalized approaches to be adopted. Lab21 is building its range to meet the needs of the pharmaceutical industry and healthcare providers to deliver on the promise that personalized medicine offers,” said Dr. Berwyn Clarke, chief scientific and development officer at Lab21.


Related Links:
Lab21

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
POC Immunoassay Analyzer
Procise DX
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more

Microbiology

view channel
Image: Overview of a rapid diagnostic workflow for fungal bloodstream infections (Photo courtesy of Professor Hiroki Takahashi and IMO, Chiba University, Japan)

Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive

Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.